联合应用吉西他滨与顺铂对蒽环类与紫杉类耐药晚期乳腺癌患者的疗效观察

目的分析并评价联合应用吉西他滨与顺铂对耐蒽环类与紫杉类晚期乳腺癌患者的临床治疗效果及不良反应。方法对我院2007年11月-2011年6月收治的68例对蒽环类与紫杉类耐药的晚期乳腺癌患者给予1 000 mg/m2吉西他滨(第1、8天)、顺铂30 mg/m2(第1～3天),21 d为1个周期,2个周期后评价疗效。结果共治疗227个周期,平均为3.34个周期。全部可评价68例患者中,CR 2例(3.0%),PR 30例(44.1%),SD 24例(35.3%),PD 12例(17.6%),总有效率为47.1%。全部患者的中位疾病进展时间为6个月,中位生存期为12.6个月。不良反应主要包括骨髓抑制及胃肠道反应。结论联合应用吉西他滨与顺铂对耐蒽环类与紫杉类晚期乳腺癌患者疗效良好,不良反应轻微,是一种理想的治疗方案。

Effect of gemcitabine combined with cisplatin on anthracycline and taxane-resistant advanced breast cancer

Objective To analyze and evaluate the therapeutic effects and adverse effects of gemcitabine combined with cisplatin on patients with advanced breast cancer resistant to anthracycline and taxane.Methods 68 patients with anthracycline/taxane-resistant advanced breast cancer admitted to our hospital from November 2007 to June 2011 were given 1 000 mg/m2 of gemcitabine(1st~8th day)and 30 mg/m2 of cisplatin(1st~3rd day)with 21 d as a cycle,the efficacy was evaluated after two cycles.Results All patients were treated with 227 cycles,the average number of cycle was 3.34.In all the evaluable patients(n=68),CR:2 cases(3.0%);PR:30 cases(44.1%);SD:24 cases(35.3%);PD:12 cases(17.6%).The total effective rate was 47.1%.The median time to progression for all patients was 6 months;the median survival period was 12.6 months.The adverse reactions included myelosuppression and gastrointestinal reactions.Conclusion Gemcitabine combined with cisplatin treatment for patients with advanced breast cancer resistant to anthracycline and taxane has desired effect,the adverse reaction is mild.It is an ideal therapeutic program.